Luisa Maria Muñoz Quiroga

Luisa Maria Muñoz Quiroga

Auto-generated profile, based on publicly available information

Luisa Maria Muñoz Quiroga

Department of Diagnostic Imaging, Fundación Santa Fe de Bogotá, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Current Medical Imaging
Verified
Journal Article
Closed access
PDF file
JOJosé David Cardona Ortegón
José David Cardona Ortegón
MYMaría Mónica Yepes
María Mónica Yepes
OROscar Mauricio Rivero Rapalino
Oscar Mauricio Rivero Rapalino
DCDavid Fernando Torres Cortes
David Fernando Torres Cortes
GRGonzalo Andres Montaño Rozo
Gonzalo Andres Montaño Rozo
LQLuisa Maria Muñoz Quiroga
Luisa Maria Muñoz Quiroga
Background: Persistent sciatic artery (PSA) is a congenital malformation due to incomplete involution during the embryonic period. Its etiology is unknown, with an estimated incidence of 0.02 - 0.04% in the whole population and a mean age of 60-65 years. Its presentation can be bilateral. It is asymptomatic in most cases and is usually detected accidentally; however, some symptoms may appear, such as claudication, sciatic neuralgia, and pain in the affected limb. It can also manifest as an aneurysmal dilatation or thrombosis that can generate distal embolism with ischemia. Case Report: In this case study, a patient in her 90s with a suspected peripheral arterial disease, which required an angiotomography of the lower limb, showing a superficial femoral artery running to the middle and distal third of the thigh and a vascular structure running in the sciatic neurovascular bundle corresponding to a persistent sciatic artery presenting atherosclerotic changes and extensive occlusion, was presented. The patient's treatment was clinical with dual antiplatelet therapy and prophylactic anticoagulation. This was due to comorbidities and age. Moreover, the PSA occlusion was not critical and did not significantly impact the patient's quality of life. Conclusion: Most patients with this anatomical variant are asymptomatic all their lives, but some of them may present symptoms with serious consequences. It is important to suspect it by clinical presentation and perform diagnostic confirmation by angiotomography. Treatment has yielded excellent results with endovascular techniques. Certain patients only require conservative treatment with anticoagulants and antiplatelet agents.

14 March 2026 in Medical Education & Clinical Practice
Verified
Journal Article
Open access
LMLuisa María Muñoz-Quiroga
Luisa María Muñoz-Quiroga
PPPaula Catalina Pérez-Sánchez
Paula Catalina Pérez-Sánchez
DLDiego Alejandro Lucero
Diego Alejandro Lucero
MDMichael Andres Davalos-Macias
Michael Andres Davalos-Macias
SVSara María Vieira-Rios
Sara María Vieira-Rios
JSJuan Santiago Serna-Trejos
Juan Santiago Serna-Trejos
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease characterized by heterogeneous clinical manifestations and driven by complex immunoinflammatory mechanisms, particularly activation of the type I interferon pathway. A subset of patients develops refractory disease, associated with increased symptom burden and significant impairment in quality of life. A narrative review of the literature was conducted using major biomedical databases, including original studies, clinical trials, systematic reviews, and relevant consensus statements. Evidence shows that, in addition to conventional therapies such as photoprotection, antimalarials, and immunosuppressive agents, targeted therapies have emerged with specific mechanisms of action, including Janus kinase inhibitors, type I interferon pathway blockers, and anti-BLyS antibodies, demonstrating efficacy in refractory CLE. These therapeutic advances support a shift toward more personalized treatment strategies, with the potential to improve clinical control and outcomes in patients with resistant disease.